272 related articles for article (PubMed ID: 27161872)
21. Leaving groups prolong the duration of 20S proteasome inhibition and enhance the potency of salinosporamides.
Manam RR; McArthur KA; Chao TH; Weiss J; Ali JA; Palombella VJ; Groll M; Lloyd GK; Palladino MA; Neuteboom ST; Macherla VR; Potts BC
J Med Chem; 2008 Nov; 51(21):6711-24. PubMed ID: 18939815
[TBL] [Abstract][Full Text] [Related]
22. Thiasyrbactins Induce Cell Death
Pierce MR; Bakas NA; Pirrung MC; Bachmann AS
Anticancer Res; 2018 Oct; 38(10):5607-5613. PubMed ID: 30275178
[TBL] [Abstract][Full Text] [Related]
23. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
[TBL] [Abstract][Full Text] [Related]
24. MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
Qiang YW; Ye S; Huang Y; Chen Y; Van Rhee F; Epstein J; Walker BA; Morgan GJ; Davies FE
BMC Cancer; 2018 Jul; 18(1):724. PubMed ID: 29980194
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibition for the treatment of glioblastoma.
Roth P; Mason WP; Richardson PG; Weller M
Expert Opin Investig Drugs; 2020 Oct; 29(10):1133-1141. PubMed ID: 32746640
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma.
Baljevic M; Orlowski RZ
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):459-473. PubMed ID: 31104525
[No Abstract] [Full Text] [Related]
27. Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.
Roy SS; Kirma NB; Santhamma B; Tekmal RR; Agyin JK
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1263-71. PubMed ID: 24728817
[TBL] [Abstract][Full Text] [Related]
28. (-)-Homosalinosporamide A and Its Mode of Proteasome Inhibition: An X-ray Crystallographic Study.
Groll M; Nguyen H; Vellalath S; Romo D
Mar Drugs; 2018 Jul; 16(7):. PubMed ID: 30029468
[TBL] [Abstract][Full Text] [Related]
29. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening.
Di Giovanni C; Ettari R; Sarno S; Rotondo A; Bitto A; Squadrito F; Altavilla D; Schirmeister T; Novellino E; Grasso S; Zappalà M; Lavecchia A
Eur J Med Chem; 2016 Oct; 121():578-591. PubMed ID: 27318981
[TBL] [Abstract][Full Text] [Related]
30. Marizomib for central nervous system-multiple myeloma.
Badros A; Singh Z; Dhakal B; Kwok Y; MacLaren A; Richardson P; Trikha M; Hari P
Br J Haematol; 2017 Apr; 177(2):221-225. PubMed ID: 28387460
[TBL] [Abstract][Full Text] [Related]
31. The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma.
Ma H; Su Z; Sun F; Zhao N
Acta Oncol; 2018 Feb; 57(2):290-296. PubMed ID: 28828905
[TBL] [Abstract][Full Text] [Related]
32. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
Qiang YW; Ye S; Chen Y; Buros AF; Edmonson R; van Rhee F; Barlogie B; Epstein J; Morgan GJ; Davies FE
Blood; 2016 Dec; 128(25):2919-2930. PubMed ID: 27793878
[TBL] [Abstract][Full Text] [Related]
33. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.
Corrales-Medina FF; Manton CA; Orlowski RZ; Chandra J
Leuk Res; 2015 Mar; 39(3):371-9. PubMed ID: 25612941
[TBL] [Abstract][Full Text] [Related]
35. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
36. Research progress in proteasome inhibitor resistance to multiple myeloma.
Wu J; Liu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):900-908. PubMed ID: 34565737
[TBL] [Abstract][Full Text] [Related]
37. NPI-0052 and γ-radiation induce a synergistic apoptotic effect in medulloblastoma.
Frisira E; Rashid F; Varma SN; Badodi S; Benjamin-Ombo VA; Michod D; Niklison-Chirou MV
Cell Death Dis; 2019 Oct; 10(11):785. PubMed ID: 31619667
[TBL] [Abstract][Full Text] [Related]
38. Molecular mechanisms of acquired proteasome inhibitor resistance.
Kale AJ; Moore BS
J Med Chem; 2012 Dec; 55(23):10317-27. PubMed ID: 22978849
[TBL] [Abstract][Full Text] [Related]
39. New orally active proteasome inhibitors in multiple myeloma.
Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
[TBL] [Abstract][Full Text] [Related]
40. Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Opoku-Ansah J; Ibarra-Rivera TR; Pirrung MC; Bachmann AS
Pharm Biol; 2012 Jan; 50(1):25-9. PubMed ID: 22196580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
